Notice Information
Notice Title
NHS Genomic Medicine Service - Most Suitable Provider Process
Notice Description
This is a notice of intention to make an award in respect of the NHS Genomic Medicine Service pursuant to the Most Suitable Provider (MSP) Process for the NHS Genomic Medicine Service (NHS GMS). For the avoidance of doubt, this is an intention to award notice. A notice of the confirmation of the award of each contract will be issued once they are signed.<br/><br/>Pursuant to the NHS GMS contracts, provider are to provide the following functions: <br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People - workforce, education and training; and<br/>* Data and digital
Lot Information
Lot 1 - NHS North-West GMS
Pursuant to the NHS GMS contracts, providers are to provide the following functions:
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital
The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.
The approximate lifetime value of the contract for all Lots is PS5,175,000,000.
The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).
Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
Options: Options to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period.
Lot 2 - NHS North-East and Yorkshire GMSPursuant to the NHS GMS contracts, providers are to provide the following functions:
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital
The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.
The approximate lifetime value of the contract for all Lots is PS5,175,000,000.
The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).
Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
Options: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period
Lot 3 - NHS Central and South GMSPursuant to the NHS GMS contracts, providers are to provide the following functions:
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital
The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.
The approximate lifetime value of the contract for all Lots is PS5,175,000,000.
The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).
Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
Options: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period
Lot 4 - NHS East GMSPursuant to the NHS GMS contracts, providers are to provide the following functions:
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital
The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.
The approximate lifetime value of the contract for all Lots is PS5,175,000,000.
The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).
Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
Options: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period
Lot 5 - NHS South-West GMSPursuant to the NHS GMS contracts, providers are to provide the following functions:
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital
The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.
The approximate lifetime value of the contract for all Lots is PS5,175,000,000.
The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).
Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
Options: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period
Lot 6 - NHS North Thames GMSPursuant to the NHS GMS contracts, providers are to provide the following functions:
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital
The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.
The approximate lifetime value of the contract for all Lots is PS5,175,000,000.
The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).
Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
Options: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period
Lot 7 - NHS South-East GMSPursuant to the NHS GMS contracts, providers are to provide the following functions:
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital
The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.
The approximate lifetime value of the contract for all Lots is PS5,175,000,000.
The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).
Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
Options: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period
Procurement Information
This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act Regulations 2023 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to decision makers by Tuesday 4th November 2025. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-h6vhtk-0565e9
- Publication Source
- Find A Tender Service
- Latest Notice
- https://www.find-tender.service.gov.uk/Notice/067976-2025
- Current Stage
- Award
- All Stages
- Planning, Award
Procurement Classification
- Notice Type
- Planning Notice
- Procurement Type
- Standard
- Procurement Category
- Services
- Procurement Method
- Limited
- Procurement Method Details
- Award procedure without prior publication of a call for competition
- Tender Suitability
- Not specified
- Awardee Scale
- Large
Common Procurement Vocabulary (CPV)
- CPV Divisions
85 - Health and social work services
-
- CPV Codes
85100000 - Health services
Notice Value(s)
- Tender Value
- £3,850,000,000 £1B-£10B
- Lots Value
- Not specified
- Awards Value
- Not specified
- Contracts Value
- £5,175,000,000 £1B-£10B
Notice Dates
- Publication Date
- 23 Oct 20254 months ago
- Submission Deadline
- Not specified
- Future Notice Date
- 17 Sep 2025Expired
- Award Date
- 20 Oct 20254 months ago
- Contract Period
- Not specified - Not specified
- Recurrence
- Not specified
Notice Status
- Tender Status
- Complete
- Lots Status
- Cancelled
- Awards Status
- Active
- Contracts Status
- Active
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- NHS ENGLAND
- Contact Name
- Anna Salt
- Contact Email
- anna.salt@nhs.net
- Contact Phone
- Not specified
Buyer Location
- Locality
- LEEDS
- Postcode
- LS1 4AP
- Post Town
- Leeds
- Country
- England
-
- Major Region (ITL 1)
- TLE Yorkshire and The Humber
- Basic Region (ITL 2)
- TLE4 West Yorkshire
- Small Region (ITL 3)
- TLE42 Leeds
- Delivery Location
- TLC North East (England), TLD North West (England), TLF East Midlands (England), TLG West Midlands (England), TLH East (England), TLI London, TLJ South East (England), TLK South West (England)
-
- Local Authority
- Leeds
- Electoral Ward
- Hunslet & Riverside
- Westminster Constituency
- Leeds South
Supplier Information
Further Information
Open Contracting Data Standard (OCDS)
View full OCDS Record for this contracting process
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.
{
"tag": [
"compiled"
],
"id": "ocds-h6vhtk-0565e9-2025-10-23T17:00:36+01:00",
"date": "2025-10-23T17:00:36+01:00",
"ocid": "ocds-h6vhtk-0565e9",
"description": "This is a Provider Selection Regime (PSR) intention to award notice. This intention to award notice is subject to Regulation 10(7) of the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act Regulations 2023 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to the relevant authority by midnight on Tuesday 4th November 2025. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.<br/>Written representations should be sent to england.genomics@nhs.net, ensuring the following details are referenced:<br/>Project reference: C368833<br/>Project title: NHS Genomic Medicine Service - Most Suitable Provider process<br/>This decision has been made as per NHS England governance processes, by the Commercial Executive Group on 14th October 2025 and the National Commissioning Group on 21st October 2025. No conflicts of Interest were identified amongst decision-makers.<br/>Each of the 5 key criteria were balanced with equal priority and considered on this basis and consideration was given to the basic selection criteria. Following provider assessments, it was agreed that the providers are the only providers capable of meeting the service specifications and requirements of the NHS GMS in full.<br/><br/>Additional CPV codes include:<br/>85145000-7 (Services provided by medical laboratories),<br/>85148000-8 (Medical analysis services)<br/>85111810-1 (Blood analysis services)<br/>85121200-5 (Medical specialist services)<br/>85140000-2 (Miscellaneous health services)",
"initiationType": "tender",
"tender": {
"id": "C368833",
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"title": "NHS Genomic Medicine Service - Most Suitable Provider Process",
"status": "complete",
"classification": {
"scheme": "CPV",
"id": "85100000",
"description": "Health services"
},
"mainProcurementCategory": "services",
"description": "This is a notice of intention to make an award in respect of the NHS Genomic Medicine Service pursuant to the Most Suitable Provider (MSP) Process for the NHS Genomic Medicine Service (NHS GMS). For the avoidance of doubt, this is an intention to award notice. A notice of the confirmation of the award of each contract will be issued once they are signed.<br/><br/>Pursuant to the NHS GMS contracts, provider are to provide the following functions: <br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People - workforce, education and training; and<br/>* Data and digital",
"value": {
"amount": 3850000000,
"currency": "GBP"
},
"lots": [
{
"id": "1",
"title": "Lot 1 - NHS North-West GMS",
"description": "Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People - workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is PS5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).",
"status": "cancelled",
"awardCriteria": {
"criteria": [
{
"name": "Most suitable provider process with regard to the key Criteria",
"type": "cost",
"description": "100"
}
]
},
"hasOptions": true,
"options": {
"description": "Options to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period."
}
},
{
"id": "2",
"title": "Lot 2 - NHS North-East and Yorkshire GMS",
"description": "Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People - workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is PS5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).",
"status": "cancelled",
"awardCriteria": {
"criteria": [
{
"name": "Most suitable provider process with regard to the key Criteria",
"type": "cost",
"description": "100"
}
]
},
"hasOptions": true,
"options": {
"description": "Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period"
}
},
{
"id": "3",
"title": "Lot 3 - NHS Central and South GMS",
"description": "Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People - workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is PS5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).",
"status": "cancelled",
"awardCriteria": {
"criteria": [
{
"name": "Most suitable provider process with regard to the key Criteria",
"type": "cost",
"description": "100"
}
]
},
"hasOptions": true,
"options": {
"description": "Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period"
}
},
{
"id": "4",
"title": "Lot 4 - NHS East GMS",
"description": "Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People - workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is PS5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).",
"status": "cancelled",
"awardCriteria": {
"criteria": [
{
"name": "Most suitable provider process with regard to the key Criteria",
"type": "cost",
"description": "100"
}
]
},
"hasOptions": true,
"options": {
"description": "Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period"
}
},
{
"id": "5",
"title": "Lot 5 - NHS South-West GMS",
"description": "Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People - workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is PS5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).",
"status": "cancelled",
"awardCriteria": {
"criteria": [
{
"name": "Most suitable provider process with regard to the key Criteria",
"type": "cost",
"description": "100"
}
]
},
"hasOptions": true,
"options": {
"description": "Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period"
}
},
{
"id": "6",
"title": "Lot 6 - NHS North Thames GMS",
"description": "Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People - workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is PS5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).",
"status": "cancelled",
"awardCriteria": {
"criteria": [
{
"name": "Most suitable provider process with regard to the key Criteria",
"type": "cost",
"description": "100"
}
]
},
"hasOptions": true,
"options": {
"description": "Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period"
}
},
{
"id": "7",
"title": "Lot 7 - NHS South-East GMS",
"description": "Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People - workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is PS5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).",
"status": "cancelled",
"awardCriteria": {
"criteria": [
{
"name": "Most suitable provider process with regard to the key Criteria",
"type": "cost",
"description": "100"
}
]
},
"hasOptions": true,
"options": {
"description": "Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period"
}
}
],
"items": [
{
"id": "1",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "85100000",
"description": "Health services"
}
],
"deliveryAddresses": [
{
"region": "UKD"
},
{
"region": "UKD"
}
],
"relatedLot": "1"
},
{
"id": "2",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "85100000",
"description": "Health services"
}
],
"deliveryAddresses": [
{
"region": "UKC"
},
{
"region": "UKC"
}
],
"relatedLot": "2"
},
{
"id": "3",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "85100000",
"description": "Health services"
}
],
"deliveryAddresses": [
{
"region": "UKF"
},
{
"region": "UKG"
}
],
"relatedLot": "3"
},
{
"id": "4",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "85100000",
"description": "Health services"
}
],
"deliveryAddresses": [
{
"region": "UKH"
},
{
"region": "UKH"
}
],
"relatedLot": "4"
},
{
"id": "5",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "85100000",
"description": "Health services"
}
],
"deliveryAddresses": [
{
"region": "UKK"
},
{
"region": "UKK"
}
],
"relatedLot": "5"
},
{
"id": "6",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "85100000",
"description": "Health services"
}
],
"deliveryAddresses": [
{
"region": "UKI"
},
{
"region": "UKI"
}
],
"relatedLot": "6"
},
{
"id": "7",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "85100000",
"description": "Health services"
}
],
"deliveryAddresses": [
{
"region": "UKJ"
},
{
"region": "UKJ"
}
],
"relatedLot": "7"
}
],
"communication": {
"futureNoticeDate": "2025-09-18T00:00:00+01:00",
"atypicalToolUrl": "https://health-family.force.com/s/Welcome"
},
"procurementMethod": "limited",
"procurementMethodDetails": "Award procedure without prior publication of a call for competition",
"procurementMethodRationaleClassifications": [
{
"scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
"id": "D_OUTSIDE_SCOPE",
"description": "The procurement falls outside the scope of application of the directive"
}
],
"procurementMethodRationale": "This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act Regulations 2023 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to decision makers by Tuesday 4th November 2025. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR."
},
"parties": [
{
"id": "GB-FTS-118033",
"name": "NHS England",
"identifier": {
"legalName": "NHS England"
},
"address": {
"streetAddress": "7&8 Wellington Place",
"locality": "Leeds",
"region": "UKE",
"postalCode": "LS1 4AP",
"countryName": "United Kingdom"
},
"contactPoint": {
"email": "anna.salt@nhs.net",
"name": "Anna Salt"
},
"roles": [
"buyer"
],
"details": {
"url": "https://www.england.nhs.uk//",
"buyerProfile": "https://www.england.nhs.uk//",
"classifications": [
{
"scheme": "TED_CA_TYPE",
"id": "BODY_PUBLIC",
"description": "Body governed by public law"
},
{
"scheme": "COFOG",
"id": "07",
"description": "Health"
}
]
}
},
{
"id": "GB-FTS-18796",
"name": "Manchester University NHS Foundation Trust",
"identifier": {
"legalName": "Manchester University NHS Foundation Trust"
},
"address": {
"locality": "Manchester",
"region": "UKD3",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-78899",
"name": "The Newcastle upon Tyne Hospitals NHS Foundation Trust",
"identifier": {
"legalName": "The Newcastle upon Tyne Hospitals NHS Foundation Trust"
},
"address": {
"locality": "Newcastle",
"region": "UKC2",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-1009",
"name": "Birmingham Women's and Children's NHS Foundation Trust",
"identifier": {
"legalName": "Birmingham Women's and Children's NHS Foundation Trust"
},
"address": {
"locality": "Birmingham",
"region": "UKG3",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-6625",
"name": "Cambridge University Hospitals NHS Foundation Trust",
"identifier": {
"legalName": "Cambridge University Hospitals NHS Foundation Trust"
},
"address": {
"locality": "Cambridge",
"region": "UKH1",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-12898",
"name": "North Bristol NHS Trust",
"identifier": {
"legalName": "North Bristol NHS Trust"
},
"address": {
"locality": "Bristol",
"region": "UKK1",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-95413",
"name": "Great Ormond Street Hospital for Children NHS Foundation Trust",
"identifier": {
"legalName": "Great Ormond Street Hospital for Children NHS Foundation Trust"
},
"address": {
"locality": "London",
"region": "UKI3",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-21063",
"name": "Guy's and St Thomas' NHS Foundation Trust",
"identifier": {
"legalName": "Guy's and St Thomas' NHS Foundation Trust"
},
"address": {
"locality": "London",
"region": "UKI3",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-141301",
"name": "NHS Arden and Greater East Midlands Commissioning Support Unit",
"identifier": {
"legalName": "NHS Arden and Greater East Midlands Commissioning Support Unit"
},
"address": {
"streetAddress": "Cardinal Square, 10 Nottingham Road",
"locality": "Derby",
"postalCode": "DE1 3QT",
"countryName": "United Kingdom"
},
"roles": [
"reviewBody"
],
"details": {
"url": "https://www.ardengemcsu.nhs.uk/"
}
}
],
"buyer": {
"id": "GB-FTS-118033",
"name": "NHS England"
},
"language": "en",
"awards": [
{
"id": "067976-2025-1",
"relatedLots": [
"1"
],
"title": "Lot 1 - NHS North-West GMS",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-18796",
"name": "Manchester University NHS Foundation Trust"
}
]
},
{
"id": "067976-2025-2",
"relatedLots": [
"2"
],
"title": "Lot 2 - NHS North-East and Yorkshire GMS",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-78899",
"name": "The Newcastle upon Tyne Hospitals NHS Foundation Trust"
}
]
},
{
"id": "067976-2025-3",
"relatedLots": [
"3"
],
"title": "Lot 3 NHS Central and South GMS",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-1009",
"name": "Birmingham Women's and Children's NHS Foundation Trust"
}
]
},
{
"id": "067976-2025-4",
"relatedLots": [
"4"
],
"title": "Lot 4 NHS East GMS",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-6625",
"name": "Cambridge University Hospitals NHS Foundation Trust"
}
]
},
{
"id": "067976-2025-5",
"relatedLots": [
"5"
],
"title": "Lot 5 NHS South-West GMS",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-12898",
"name": "North Bristol NHS Trust"
}
]
},
{
"id": "067976-2025-6",
"relatedLots": [
"6"
],
"title": "Lot 6 NHS North Thames GMS",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-95413",
"name": "Great Ormond Street Hospital for Children NHS Foundation Trust"
}
]
},
{
"id": "067976-2025-7",
"relatedLots": [
"7"
],
"title": "Lot 7 NHS South-East GMS",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-21063",
"name": "Guy's and St Thomas' NHS Foundation Trust"
}
]
}
],
"contracts": [
{
"id": "067976-2025-1",
"awardID": "067976-2025-1",
"title": "Lot 1 - NHS North-West GMS",
"status": "active",
"value": {
"amount": 5175000000,
"currency": "GBP"
},
"dateSigned": "2025-10-21T00:00:00+01:00"
},
{
"id": "067976-2025-2",
"awardID": "067976-2025-2",
"title": "Lot 2 - NHS North-East and Yorkshire GMS",
"status": "active",
"value": {
"amount": 5175000000,
"currency": "GBP"
},
"dateSigned": "2025-10-21T00:00:00+01:00"
},
{
"id": "067976-2025-3",
"awardID": "067976-2025-3",
"title": "Lot 3 NHS Central and South GMS",
"status": "active",
"value": {
"amount": 5175000000,
"currency": "GBP"
},
"dateSigned": "2025-10-21T00:00:00+01:00"
},
{
"id": "067976-2025-4",
"awardID": "067976-2025-4",
"title": "Lot 4 NHS East GMS",
"status": "active",
"value": {
"amount": 5175000000,
"currency": "GBP"
},
"dateSigned": "2025-10-21T00:00:00+01:00"
},
{
"id": "067976-2025-5",
"awardID": "067976-2025-5",
"title": "Lot 5 NHS South-West GMS",
"status": "active",
"value": {
"amount": 5175000000,
"currency": "GBP"
},
"dateSigned": "2025-10-21T00:00:00+01:00"
},
{
"id": "067976-2025-6",
"awardID": "067976-2025-6",
"title": "Lot 6 NHS North Thames GMS",
"status": "active",
"value": {
"amount": 5175000000,
"currency": "GBP"
},
"dateSigned": "2025-10-21T00:00:00+01:00"
},
{
"id": "067976-2025-7",
"awardID": "067976-2025-7",
"title": "Lot 7 NHS South-East GMS",
"status": "active",
"value": {
"amount": 5175000000,
"currency": "GBP"
},
"dateSigned": "2025-10-21T00:00:00+01:00"
}
],
"bids": {
"statistics": [
{
"id": "1",
"measure": "bids",
"relatedLot": "1",
"value": 3
},
{
"id": "2",
"measure": "bids",
"relatedLot": "2",
"value": 3
},
{
"id": "3",
"measure": "bids",
"relatedLot": "3",
"value": 3
},
{
"id": "4",
"measure": "bids",
"relatedLot": "4",
"value": 3
},
{
"id": "5",
"measure": "bids",
"relatedLot": "5",
"value": 3
},
{
"id": "6",
"measure": "bids",
"relatedLot": "6",
"value": 3
},
{
"id": "7",
"measure": "bids",
"relatedLot": "7",
"value": 3
}
]
}
}